Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-01-11
2011-01-11
Zeman, Robert A (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C530S350000
Reexamination Certificate
active
07867982
ABSTRACT:
The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
REFERENCES:
patent: 5169763 (1992-12-01), Kieny et al.
patent: 5185146 (1993-02-01), Altenburger
patent: 5256767 (1993-10-01), Salk et al.
patent: 5445953 (1995-08-01), Dorner et al.
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5614404 (1997-03-01), Mazzara et al.
patent: 5676950 (1997-10-01), Small et al.
patent: 5736368 (1998-04-01), Mazzara et al.
patent: 5741492 (1998-04-01), Hurwitz et al.
patent: 5747324 (1998-05-01), Mazzara et al.
patent: 5747338 (1998-05-01), Giese et al.
patent: 5756103 (1998-05-01), Paoletti et al.
patent: 5766599 (1998-06-01), Paoletti et al.
patent: 5795577 (1998-08-01), Kieny et al.
patent: 5817637 (1998-10-01), Weiner et al.
patent: 5846946 (1998-12-01), Huebner et al.
patent: 5849304 (1998-12-01), Moss et al.
patent: 5853725 (1998-12-01), Salk et al.
patent: 5858775 (1999-01-01), Johnson
patent: 5863542 (1999-01-01), Paoletti et al.
patent: 5879925 (1999-03-01), Rovinski et al.
patent: 5911989 (1999-06-01), Katinger et al.
patent: 5928930 (1999-07-01), Salk et al.
patent: 5985641 (1999-11-01), Haynes et al.
patent: 6051410 (2000-04-01), Mazzara et al.
patent: 6077662 (2000-06-01), Compans et al.
patent: 6080408 (2000-06-01), Rovinski et al.
patent: 6086891 (2000-07-01), Hurwitz et al.
patent: 6099847 (2000-08-01), Tobin et al.
patent: 6103244 (2000-08-01), Dorner et al.
patent: 6121021 (2000-09-01), Rovinski et al.
patent: 6140114 (2000-10-01), Klatzmann et al.
patent: 6156952 (2000-12-01), Bryant et al.
patent: 6171596 (2001-01-01), Earl et al.
patent: 6204250 (2001-03-01), Bot et al.
patent: 6210663 (2001-04-01), Ertl
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6265183 (2001-07-01), Dorner et al.
patent: 6291157 (2001-09-01), Rovinski et al.
patent: 6306625 (2001-10-01), Jacobs et al.
patent: 6448083 (2002-09-01), Larocca et al.
patent: 6544527 (2003-04-01), Rovinski et al.
patent: 6663871 (2003-12-01), McMichael et al.
patent: 335 635 (1989-03-01), None
patent: 0 538 496 (1991-08-01), None
patent: WO89/09260 (1989-10-01), None
patent: WO 89/12095 (1989-12-01), None
patent: WO 91/07425 (1991-05-01), None
patent: WO 92/08789 (1992-05-01), None
patent: WO 97/27311 (1997-07-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/63098 (1999-12-01), None
patent: WO 00/00216 (2000-01-01), None
patent: WO 01/47955 (2000-07-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/52886 (2001-07-01), None
patent: WO 01/82962 (2001-11-01), None
patent: WO 01/92470 (2001-12-01), None
patent: WO 02/072754 (2002-09-01), None
patent: WO 03/004657 (2003-01-01), None
Andersson et al., Cloning, Structure, and Expression of the Mitochondrial Cytochrome . . . J. of Biol. Chem. 264(14):8222-8229, 1989.
Belyakov et al., “Induction of a Mucosal Cytotoxic T-Lymphocyte Response by . . . ” J. of Virology 72(1):8264-8272, 1998.
Cheonis, N., “Status Report on HIV Vaccine Development” Status Report on HIV Vaccine Development retrieved from internet >http://www.thebody.com/sfaf/winter00/vaccine.html. Oct. 2001.
Davison et al., “Structure of Vaccinia Virus Early Promoters” J. Mol. Biol. 210:749-769, 1989.
Hanke et al., “Enhancement of MHC class I-restricted peptide-specific T cell induction . . . ” Vaccine 16(5):439-445, 1998.
Hanke et al., “Lack of toxicity and persistence in the mouse associated with administration of candidate . . . ” Vaccine 21:108-114, 2002.
Hanke et al., “Development of a DNA-MVA/HIVA vaccine for Kenya” Vaccine 20:1995-1998, 2002.
Hanke et al., “Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS” Immunology Letters 66:177-181, 1999.
Hanke et al., “Effective induction of HIV-specific CTL by multi-epitope using gene gun . . . ” Vaccine 17:589-596, 1999.
Hanke et al., “Immunogenicities of intravenous and intramuscular administrations of modified vaccinia . . . ” J. of General Virology 79:83-90, 1998.
Haffar et al., “The Carboxy Terminus of Human Immunodeficiency Virus Type I gp160 . . . ” J. of Virology 64(6):3100-3103, 1990.
Ho, M., “Aids Vaccines Trials Dangerous” retrieved from internet http://www.i-sis.org.uk/isisnews/i-sisnews11-19.php. Oct. 2001.
Masternak et al., “cis- and trans-Acting Elements Involved in Reactivation of Vaccinia Virus Early Transcription” J. of Virology 70(12):8737-8746, 1996.
Woe et al., “A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces . . . ”J. of General Virology 83:75-80, 2002.
Wyatt et al., “Development of a replication-deficient recombinant vaccinia virus vaccine effective against . . . ” Vaccine 14(15):1451-1458, 1996.
Wyatt et al., “Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective . . . ” Vacine 18:392-397, 2000.
Amara et al., “Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines,”J. Virology76:7625-7631 (2002).
Andre et al., “Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codons usage,” J. Virol., 72: 1497-1503, 1998.
Antoine et al., “The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses”, Virology, 244: 365-96, 1998.
Asakara et al., “Induction of HIV-1 specific mucosal immune responses by DNA vaccination,” Scand. J. Immunol., 46: 326-330, 1997.
Bachmann and Zinkernagel, “Neutralizing antiviral B cell responses,” in Ann. Rev. Immunol., 15: 235-270, 1997.
Barouch et al., “Reduction of Simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination,” J. Virol., 75: 5151-5158, 2001.
Barouch et al., “Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA caccines by IL-2/IG plasmid administration in rhesus monkeys”, Proc. Natl. Acad. Sci. U.S.A., 97:4192-7, Apr. 11, 2000.
Barry et al., “Protection against mycoplasma infection using expression-library immunization,” Nature, 377: 632-635, 1995.
Berger, “HIV Entry and Tropism: the chemokine receptor connection,” AIDS, 11(Suppl. A): S3-16, 1997.
Benson et al., J. Virol., “Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure,” 72: 4170-4182, 1998.
Blanchard et al., “Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine,” J. Gen. Virol., 79: 1159-1167, 1998.
Bohm et al., “DNA vector constructs that prime hepatitis B surface antigen-specific cytotoxic T lymphocyte and antibody responses in mice after intramuscular injection,” J. Immuno. Methods, 193: 29-40, 1996.
Bohm et al., “Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses,” Vaccine, 16: 949-54, 1998.
Bolivar et al., “Construction and Characterization of New Cloning Vehicles: (II. A Multipurpose Cloning System),” Gene, 2: 95-113, 1977.
Boyer et al., “Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination,” Nature Med., 3: 526-532, 1997.
Boyle et al., “Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization,” Int. Immunol., 9: 1897-190
Earl Patricia
Moss Bernard
Robinson Harriet L.
Wyatt Linda
Emory University
Fish & Richardson P.C.
Zeman Robert A
LandOfFree
MVA expressing modified HIV envelope, gag, and pol genes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MVA expressing modified HIV envelope, gag, and pol genes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MVA expressing modified HIV envelope, gag, and pol genes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668666